[1] BrantlyM, Nukiwa T, Crystal RG. Molecular basis of alpha-1-antitrypsin deficiency[J]. Am J Med,1988,84(6A):13-31.
[2] StrnadP, McElvaney NG, Lomas DA. Alpha1-Antitrypsin Deficiency[J]. N Engl J Med, 2020,382(15):1443-1455.
[3] TownsendSA, Edgar RG, Ellis PR, et al. Systematic review: the natural history of alpha-1 antitrypsin deficiency, and associated liver disease[J]. Aliment Pharmacol Ther,2018,47(7):877-885.
[4] FriedrichM, Aigner A. Therapeutic siRNA: State-of-the-Art and Future Perspectives[J]. BioDrugs Clin Immunother Biopharm Gene Ther,2022,36(5):549-571.
[5] ClarkVC, Strange C, Strnad P, et al. Fazirsiran for Adults With Alpha-1 Antitrypsin Deficiency Liver Disease: A Phase 2 Placebo Controlled Trial (SEQUOIA)[J]. Gastroenterology, 2024,167(5):1008-1018.
[6] HwangJ, Qi L. Quality Control in the Endoplasmic Reticulum: Crosstalk between ERAD and UPR pathways[J]. Trends Biochem Sci,2018,43(8):593-605.
[7] TeckmanJH, An JK, Loethen S, et al. Fasting in alpha1-antitrypsin deficient liver: constitutive[correction of consultative] activation of autophagy[J]. Am J Physiol Gastrointest Liver Physiol, 2002,283(5):G1156-1165.
[8] PatelD, Teckman JH. Alpha-1-Antitrypsin Deficiency Liver Disease[J]. Clin Liver Dis,2018,22(4):643-655.
[9] HidvegiT, Schmidt BZ, Hale P, et al. Accumulation of mutant alpha1-antitrypsin Z in the endoplasmic reticulum activates caspases-4 and -12, NFkappaB, and BAP31 but not the unfolded protein response[J]. J Biol Chem,2005,280(47):39002-39015.
[10] PerlmutterDH, Brodsky JL, Balistreri WF, et al. Molecular pathogenesis of alpha-1-antitrypsin deficiency-associated liver disease: a meeting review[J]. Hepatology, 2007,45(5):1313-1323.
[11] HameschK, Mandorfer M, Pereira VM, et al. Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation[J]. Gastroenterology,2019,157(3):705-719.
[12] SvegerT. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants[J]. N Engl J Med,1976,294(24):1316-1321.
[13] MostafaviB, Piitulainen E, Tanash H. Survival in the Swedish cohort with alpha-1-antitrypsin deficiency, up to the age of 43-45 years[J]. Int J Chron Obstruct Pulmon Dis,2019,14:525-530.
[14] TanashHA, Ekström M, Wagner P, et al. Cause-specific mortality in individuals with severe alpha 1-antitrypsin deficiency in comparison with the general population in Sweden[J]. Int J Chron Obstruct Pulmon Dis,2016,11:1663-1669.
[15] HillerA, Ekström M, Piitulainen E, et al. Cancer risk in severe alpha-1-antitrypsin deficiency[J]. Eur Respir J,2022,60(4):2103200.
[16] HameschK, Strnad P. Non-Invasive Assessment and Management of Liver Involvement in Adults With Alpha-1 Antitrypsin Deficiency[J]. Chronic Obstr Pulm Dis, 2020,7(3):260-271.
[17] SettenRL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics[J]. Nat Rev Drug Discov, 2019,18(6):421-446.
[18] CrookeST, Witztum JL, Bennett CF, et al. RNA-Targeted Therapeutics[J]. Cell Metab, 2018,27(4):714-739.
[19] WooddellCI, Blomenkamp K, Peterson RM, et al. Development of an RNAi therapeutic for alpha-1-antitrypsin liver disease[J]. JCI Insight, 2020,5(12):e135348, 135348.
[20] MelaM, Smeeton W, Davies S, et al. The Alpha-1 Antitrypsin Polymer Load Correlates With Hepatocyte Senescence, Fibrosis Stage and Liver-Related Mortality[J]. Chronic Obstr Pulm Dis ,2020,7(3):151-162. |
